BAVA:CPH
Bavarian Nordic
DKK 241,00
arrow_downward
-0,08%(-0,20) 1D
13 okt, 09:19:35 GMT+2 · DKK
search
Alle symbolen
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor BAVA genereren…
Openen
DKK 240,00
Hoog
DKK 242,20
Laag
DKK 240,00
Beursw.
18,77 mld.
Gem. vol.
179,17K
Volume
18,02K
52 wk hoog
DKK 243,70
52 wk laag
DKK 171,30
Uitstaande aandelen
79,27 mln.
Aantal medewerkers
2K
Openen
DKK 240,00
Hoog
DKK 242,20
Laag
DKK 240,00
Beursw.
18,77 mld.
Gem. vol.
179,17K
Volume
18,02K
52 wk hoog
DKK 243,70
52 wk laag
DKK 171,30
Uitstaande aandelen
79,27 mln.
Aantal medewerkers
2K
Nieuwsartikelen
Van webbronnen en nieuwspartners
GlobeNewswire
·
15 uur geleden
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
Profiel
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
Over Bavarian Nordic